United Therapeutics (NASDAQ:UTHR) announced eight presentations at the 2026 European Society of Cardiology and European Respiratory Society congresses covering investigational therapies for pulmonary arterial hypertension and other lung diseases.
iBio (NASDAQ:IBIO) reported fiscal 2026 results as it advanced into clinical-stage development, with its Phase 1 trial of IBIO-600 progressing after 31 of 32 participants were dosed across four cohorts.
Eli Lilly (NYSE:LLY) received U.S. FDA approval for an expanded indication of Mounjaro (tirzepatide) to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk.
Quoin Pharmaceuticals (NASDAQ:QNRX) reported positive interim results from its Phase 2/3 CL-QRX003-004 study showing QRX003 4% lotion met its primary endpoint in the first six participants with Netherton Syndrome.
HUTCHMED (NASDAQ:HCM) received conditional approval from China’s National Medical Products Administration for ATLED® (fanregratinib, HMPL-453), an oral FGFR 1/2/3 inhibitor for certain adults with advanced intrahepatic cholangiocarcinoma.
AstraZeneca (NASDAQ:AZN) and Amgen (NASDAQ:AMGN) reported Phase III CROSSING trial results showing TEZSPIRE® (tezepelumab-ekko) achieved statistically significant improvements in eosinophilic esophagitis outcomes, with benefits maintained through week 52.
Mesoblast (NASDAQ:MESO) reported FY2026 total revenue of $120.3 million, up from $17.2 million a year earlier, as the company recorded its first full U.S. commercial year of Ryoncil sales.
AbbVie (NYSE:ABBV) submitted a regulatory application to the European Medicines Agency for subcutaneous SKYRIZI (risankizumab) induction treatment in adults with moderately to severely active Crohn’s disease.
Amgen (NASDAQ:AMGN) and AstraZeneca (NYSE:AZN) reported positive Phase 3 results from the CROSSING trial of TEZSPIRE (tezepelumab-ekko), with the study meeting both primary endpoints in 368 patients with symptomatic eosinophilic esophagitis.
Daiichi Sankyo and AstraZeneca (NYSE:AZN) dosed the first patient in the phase 3 TROPION-Urothelial04 trial evaluating Datroway plus rilvegostomig or Datroway monotherapy in patients with high-risk muscle invasive urothelial cancer.
Biohaven (NYSE:BHVN) signed an exclusive global licensing agreement with SK Biopharmaceuticals for its Kv7 platform valued up to $795 million.
BeOne Medicines (NASDAQ:ONC) received U.S. FDA approval for TEVIMBRA (tislelizumab) combined with ZIIHERA (zanidatamab) and chemotherapy as a first-line treatment for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma.
-640x360.webp&w=3840&q=75)
